Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate how non-Hodgkin's lymphoma that has not responded to, or that has returned after standard treatment, responds to bortezomib, rituximab and bendamustine, and also to see what effects this drug combination have on this cancer.
Non-Hodgkin's Lymphoma
DRUG: bortezomib|DRUG: bendamustine|DRUG: rituximab
Number of Participants With Progression Free Survival at 2 Years, To determine the progression-free survival following treatment with the BVR combination in patients with relapsed or refractory indolent and mantle cell non-Hodgkin lymphoma., Two years
Toxicity of Drug Combination in the Subjects, Two years|Overall Response Rate (ORR), Overall response rate (ORR)to protocol treatment - Partial response, Complete response, etc., Two years
The purpose of this study is to evaluate how non-Hodgkin's lymphoma that has not responded to, or that has returned after standard treatment, responds to bortezomib, rituximab and bendamustine, and also to see what effects this drug combination have on this cancer.